Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Conatus Pharmaceuticals’ study of emricasan for non-alcoholic steatohepatitis found the drug had no significant impact.
Researchers analyzed health data regarding modern hep C treatments specific to New South Wales.
Researchers reached this conclusion after reviewing data on more than 30,000 people.
Scientists have firmly established an association between direct-acting antiviral treatment and a lower risk of liver cancer and death.
Better antiretrovirals have likely mitigated HIV’s effects on the risk of end-stage liver disease and liver cancer in those with hep C.
Researchers followed nearly 10,000 people with hepatitis C, some of whom were treated with direct-acting antivirals.
Indicators of liver health improved at the same rate among those with cirrhosis who were cured of hep C regardless of their HIV status.
Caring for someone with cirrhosis is hard work and much harder when there is hepatic encephalopathy.
Liver disease such as viral hepatitis and other liver conditions can cause damage to the liver which can range from mild to severe.
This is according to an analysis of nearly 5,000 Italians recently treated for the virus.
A European liver transplant registry saw a decline in hep C as a cause of needing a transplant.
A recent study analyzed health outcomes among those with decompensated cirrhosis treated with Sovaldi-based regimens.
Use of drugs like Nexium or Prilosec is tied to progression to cirrhosis, decompensated cirrhosis and liver cancer in this population.
Highlights from research presented at the 52nd International Liver Congress in Amsterdam
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.